Zobrazeno 1 - 10
of 46
pro vyhledávání: '"Robert L Dobbins"'
Autor:
Chun S Zuo, Young-Hoon Sung, Donald C Simonson, Erin Habecker, Jian Wang, Charlotte Haws, Rosemond A Villafuerte, Michael E Henry, Robert L Dobbins, Rebecca J Hodge, Derek J R Nunez, Perry F Renshaw
Publikováno v:
PLoS ONE, Vol 7, Iss 11, p e49337 (2012)
Tissue water transverse relaxation times (T2) are highly sensitive to fluid and lipid accumulations in skeletal muscles whereas the related T2* is sensitive to changes in tissue oxygenation in addition to factors affecting T2. Diabetes mellitus (DM)
Externí odkaz:
https://doaj.org/article/2aec47d07050428cae6156a63eefa06d
Autor:
Erik Olofsen, Marijke Hyke Algera, Laurence Moss, Robert L. Dobbins, Geert J. Groeneveld, Monique van Velzen, Marieke Niesters, Albert Dahan, Celine M. Laffont
Publikováno v:
JCI Insight, Vol 7, Iss 9 (2022)
BACKGROUND Potent synthetic opioids, such as fentanyl, are increasingly abused, resulting in unprecedented numbers of fatalities from respiratory depression. Treatment with the high-affinity mu-opioid receptor partial agonist buprenorphine may preven
Externí odkaz:
https://doaj.org/article/faf5c86fc2f348318525716d62bbc243
Autor:
Howard Hassman, Stephanie Strafford, Sunita N. Shinde, Amy Heath, Brent Boyett, Robert L. Dobbins
Background: For patients with opioid use disorder, buprenorphine extended-release injection (BUP-XR) achieves sustained therapeutic plasma concentrations, controls craving and withdrawal symptoms, and improves patient outcomes. Given retention challe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::60ccc036b9e787a1f9820d8c8bfce52b
Autor:
Erik Olofsen, Marijke Hyke Algera, Laurence Moss, Robert L. Dobbins, Geert J. Groeneveld, Monique van Velzen, Marieke Niesters, Albert Dahan, Celine M. Laffont
Publikováno v:
JCI Insight, 7(9). AMER SOC CLINICAL INVESTIGATION INC
BACKGROUND. Potent synthetic opioids, such as fentanyl, are increasingly abused, resulting in unprecedented numbers of fatalities from respiratory depression. Treatment with the high-affinity mu-opioid receptor partial agonist buprenorphine may preve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d90762cbd5394b2b14892fc6308c7043
https://pubmed.ncbi.nlm.nih.gov/35316224
https://pubmed.ncbi.nlm.nih.gov/35316224
Autor:
Antonella Napolitano, Sam Miller, Peter R. Murgatroyd, Elizabeth Hussey, Robert L. Dobbins, Edward T. Bullmore, Derek J.R. Nunez
Publikováno v:
Journal of Clinical & Translational Endocrinology, Vol 1, Iss 1, Pp e3-e8 (2014)
Inhibitors of sodium-dependent glucose co-transporter 2 (SGLT2) increase glucose excretion in the urine and improve blood glucose in Type 2 diabetes mellitus. Glycosuria provides an energy and osmotic drain that could alter body composition. We there
Externí odkaz:
https://doaj.org/article/6b472b7c565f46638093142889ba81e0
Autor:
Laurence M Moss, Jules A. A. C. Heuberger, Robert L. Dobbins, Marieke Niesters, Celine M. Laffont, Erik Olofsen, Marijke Hyke Algera, Albert Dahan, Monique van Velzen, Geert Jan Groeneveld
Publikováno v:
Clinical Pharmacology and Therapeutics
Clinical Pharmacology & Therapeutics, 109(3), 637-645. WILEY
Clinical Pharmacology & Therapeutics, 109(3), 637-645. WILEY
Chronic opioid consumption is associated with addiction, physical dependence, and tolerance. Tolerance results in dose escalation to maintain the desired opioid effect. Intake of high-dose or potent opioids may cause life-threatening respiratory depr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45daf3ef8be6da98261915a671efea18
https://pubmed.ncbi.nlm.nih.gov/32865832
https://pubmed.ncbi.nlm.nih.gov/32865832
Autor:
Douglas Thompson, Robert L. Dobbins, Duncan Richards, Stuart Kendrick, Margaret Corrigan, Ulrich Beuers, George E. Dukes, James Storey, David Jones, Gideon M. Hirschfield, Sam R. Miller, Ronald P.J. Oude Elferink, Vinod S. Hegade
Publikováno v:
Lancet, 389(10074), 1114-1123. Elsevier Limited
Background Up to 70% of patients with primary biliary cholangitis develop pruritus (itch) during the course of their disease. Treatment of pruritus in primary biliary cholangitis is challenging and novel therapies are needed. Ursodeoxycholic acid, th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::464c43763c14fc0ad022460ae7d576c8
https://doi.org/10.1016/s0140-6736(17)30319-7
https://doi.org/10.1016/s0140-6736(17)30319-7
Autor:
Sam R. Miller, Vinod S. Hegade, Susan Vallow, Robert L. Dobbins, George E. Dukes, Margaret Corrigan, James Storey, Duncan Richards, Stuart Kendrick, David Jones, Graeme J.M. Alexander, Gideon M. Hirschfield, Kim Gilchrist
Publikováno v:
BMC Gastroenterology
Background Pruritus (itch) is a symptom commonly experienced by patients with cholestatic liver diseases such as primary biliary cholangitis (PBC, previously referred to as primary biliary cirrhosis). Bile acids (BAs) have been proposed as potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f2234c33fb3df880594322de63a1a2a
https://ora.ox.ac.uk/objects/uuid:75a2d000-7488-4c92-bfb2-399cc1427fae
https://ora.ox.ac.uk/objects/uuid:75a2d000-7488-4c92-bfb2-399cc1427fae
Autor:
Yaping Liu, Lihong Chen, Frank L. Greenway, Robert L. Dobbins, Chari D. Smith, Susan Andrews, Jeffrey A. Wald, Ann C. Walker, Sharon L Breed
Publikováno v:
American Journal of Physiology-Gastrointestinal and Liver Physiology. 308:G946-G954
GSK-1614235 and KGA-2727 are potent, selective inhibitors of the SGLT1 sodium-dependent glucose transporter. Nonclinical (KGA-2727) and clinical (GSK-1614235) trials assessed translation of SGLT1 inhibitor effects from rats to normal human physiology
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2fd76e344ef5f98ec3265dbb6372922
https://doi.org/10.1152/ajpgi.00286.2014
https://doi.org/10.1152/ajpgi.00286.2014
Autor:
L. Kler, D. J. Dorey, W. O. Wilkison, S. Walker, Robert L. Dobbins, Robin L. O'Connor-Semmes, A. P. Sykes, J. D. Lorimer
Publikováno v:
Diabetes, Obesity and Metabolism. 17:94-97
We compared the efficacy of twice-daily doses of remogliflozin etabonate (RE) and once-daily pioglitazone with placebo for reduction in glycated haemoglobin (HbA1c) concentration. In this 12-week, double-blind, randomized, active- and placebo-control
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51226f4d7f15c5ffab9fe84e2cbd26c6
https://doi.org/10.1111/dom.12391
https://doi.org/10.1111/dom.12391